<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="793" width="595">
	<fontspec id="0" size="10" family="LKMMPM+Univers-CondensedBold" color="#000000"/>
	<fontspec id="1" size="8" family="LKMMPN+Univers-Condensed" color="#000000"/>
	<fontspec id="2" size="8" family="LKMMPM+Univers-CondensedBold" color="#000000"/>
	<fontspec id="3" size="9" family="LKMNDC+Minion" color="#000000"/>
	<fontspec id="4" size="9" family="LKMNDD+Minion" color="#000000"/>
	<fontspec id="5" size="9" family="LKNLEA+MTMI" color="#000000"/>
	<fontspec id="6" size="7" family="LKMNDC+Minion" color="#000000"/>
	<fontspec id="7" size="12" family="LKMMPM+Univers-CondensedBold" color="#000000"/>
<text top="279" left="52" width="33" height="9" font="0"><b>Figure 5.</b></text>
<text top="280" left="94" width="346" height="8" font="1">Inhibitory effects of SMAD6 variants on BMP signaling monitored via alkaline phosphatase (ALP) activity.</text>
<text top="280" left="441" width="5" height="8" font="2"><b>A</b></text>
<text top="280" left="446" width="97" height="8" font="1">: ALP activity of constitutively</text>
<text top="289" left="52" width="490" height="8" font="1">active BMPR1A (caBMPR1A)-transfected C2C12 cells with and without SMAD6c variants was measured as absorbance at 405 nm per mg/ml protein.</text>
<text top="298" left="52" width="5" height="8" font="2"><b>B</b></text>
<text top="298" left="58" width="485" height="8" font="1">: Immunoblots show levels of expression of caBMPR1A and SMAD6 protein; endogenous nucleolin was used as a loading control. SMAD6 (pC485F)</text>
<text top="307" left="52" width="356" height="8" font="1">showed significant loss of inhibitory activity, whereas there was no detectable effect of SMAD6 (pP415L).</text>
<text top="345" left="52" width="239" height="9" font="3">variant allele was found to have a bicuspid aortic valve with mild</text>
<text top="356" left="52" width="239" height="9" font="3">aortic stenosis and aortic coarctation at the age of 30 years in the</text>
<text top="367" left="52" width="239" height="9" font="3">course of investigation for hypertension, and the coarctation was</text>
<text top="378" left="52" width="239" height="9" font="3">repaired. He subsequently developed significant aortic stenosis and</text>
<text top="389" left="52" width="239" height="9" font="3">underwent aortic valve replacement and rerepair of the aortic arch.</text>
<text top="400" left="52" width="239" height="9" font="3">At his second operation, it was noted that the transverse aortic arch,</text>
<text top="411" left="52" width="239" height="9" font="3">proximal to and distant from the previous conduit, was heavily calci-</text>
<text top="422" left="52" width="239" height="9" font="3">fied. It is possible that this is a consequence of the reduced efficiency</text>
<text top="433" left="52" width="239" height="9" font="3">of the p.C484F mutant SMAD6 in inhibiting osteogenic potential</text>
<text top="444" left="52" width="239" height="9" font="3">(Fig. 5). There was no evidence of inappropriate calcification in</text>
<text top="455" left="52" width="94" height="9" font="3">noncardiovascular tissues.</text>
<text top="466" left="61" width="230" height="9" font="3">The other functionally significant SMAD6 variant we discovered</text>
<text top="477" left="52" width="239" height="9" font="3">(p.P415L) was present in a patient who presented with a heart mur-</text>
<text top="487" left="52" width="239" height="9" font="3">mur at 18 months and was found to have a bicuspid aortic valve</text>
<text top="498" left="52" width="239" height="9" font="3">with moderate aortic stenosis. There was no evidence of coarctation.</text>
<text top="509" left="52" width="163" height="9" font="3">Both patients carrying functionally significant</text>
<text top="509" left="218" width="28" height="9" font="4"><i>SMAD6</i></text>
<text top="509" left="248" width="44" height="9" font="3">variants had</text>
<text top="520" left="52" width="239" height="9" font="3">bicuspid aortic valves, the commonest cardiovascular malforma-</text>
<text top="531" left="52" width="239" height="9" font="3">tion, occurring in approximately 1% of the adult population. There</text>
<text top="542" left="52" width="239" height="9" font="3">is a phenotypic spectrum in this condition dependent on the degree</text>
<text top="553" left="52" width="239" height="9" font="3">of valvular malformation, ranging from severe aortic stenosis in the</text>
<text top="564" left="52" width="239" height="9" font="3">neonatal period to the usual presentation either as an asymptomatic</text>
<text top="575" left="52" width="239" height="9" font="3">murmur or established aortic stenosis in adult life. As this cohort</text>
<text top="586" left="52" width="239" height="9" font="3">of CVM cases was mainly recruited through a pediatric cardiology</text>
<text top="597" left="52" width="239" height="9" font="3">service, the numbers with bicuspid aortic valve were relatively small</text>
<text top="608" left="52" width="158" height="9" font="3">(24/436). It will be interesting to test whether</text>
<text top="608" left="212" width="28" height="9" font="4"><i>SMAD6</i></text>
<text top="608" left="242" width="49" height="9" font="3">mutations are</text>
<text top="619" left="52" width="239" height="9" font="3">over-represented in a larger cohort of CVM patients with bicuspid</text>
<text top="630" left="52" width="161" height="9" font="3">aortic valves and other aortic malformations.</text>
<text top="641" left="61" width="23" height="9" font="3">In the</text>
<text top="641" left="87" width="24" height="9" font="4"><i>Smad6</i></text>
<text top="641" left="115" width="176" height="9" font="3">knockout mouse originally described by Galvin</text>
<text top="652" left="52" width="239" height="9" font="3">et al. (2000), multiple cardiovascular developmental abnormalities,</text>
<text top="663" left="52" width="239" height="9" font="3">including hyperplastic thickening of the cardiac valves and aortic</text>
<text top="674" left="52" width="152" height="9" font="3">ossification, are present. The association of</text>
<text top="674" left="207" width="28" height="9" font="4"><i>SMAD6</i></text>
<text top="674" left="237" width="55" height="9" font="3">mutations with</text>
<text top="685" left="52" width="239" height="9" font="3">an aortic stenosis phenotype in the patients described in this study</text>
<text top="696" left="52" width="239" height="9" font="3">is entirely consistent with those observations and with a similar role</text>
<text top="707" left="52" width="239" height="9" font="3">for SMAD6 in human cardiovascular development. Our findings are</text>
<text top="718" left="52" width="239" height="9" font="3">also consistent with the expression of SMAD6 in the cardiac valves</text>
<text top="729" left="52" width="239" height="9" font="3">and outflow tract, which continues into adult life in mouse [Galvin</text>
<text top="740" left="52" width="239" height="9" font="3">et al., 2000], and with a recent clinical phenotypic study showing</text>
<text top="345" left="303" width="239" height="9" font="3">that reduced SMAD6 expression was associated with calcification of</text>
<text top="356" left="303" width="133" height="9" font="3">the aortic valve [Ankeny et al., 2011].</text>
<text top="367" left="312" width="184" height="9" font="3">Exon-focused sequencing of two other genes (</text>
<text top="367" left="496" width="28" height="9" font="4"><i>BMPR2</i></text>
<text top="367" left="529" width="14" height="9" font="3">and</text>
<text top="378" left="303" width="33" height="9" font="4"><i>BMPR1A</i></text>
<text top="378" left="337" width="206" height="9" font="3">) in the BMP signaling pathway revealed no nonsynony-</text>
<text top="389" left="303" width="239" height="9" font="3">mous variants. We therefore conclude that such variants are uncom-</text>
<text top="400" left="303" width="239" height="9" font="3">mon in these genes in CVM patients; however, sequencing of much</text>
<text top="411" left="303" width="239" height="9" font="3">larger number of cases would be required to exclude prevalences</text>
<text top="422" left="303" width="239" height="9" font="3">of 1–2%. On the basis of information from mouse models, there is</text>
<text top="433" left="303" width="239" height="9" font="3">a significant involvement of other BMP- and transforming growth</text>
<text top="444" left="303" width="21" height="9" font="3">factor</text>
<text top="444" left="326" width="5" height="8" font="5"><i>β</i></text>
<text top="444" left="333" width="20" height="9" font="3">(TGF</text>
<text top="444" left="352" width="5" height="8" font="5"><i>β</i></text>
<text top="444" left="357" width="185" height="9" font="3">)-related genes in cardiac development that also war-</text>
<text top="455" left="303" width="239" height="9" font="3">rants further investigation in congenital heart disease [Arthur and</text>
<text top="466" left="303" width="239" height="9" font="3">Bamforth, 2011; Wang et al., 2011]. Variants in some of these genes</text>
<text top="477" left="303" width="239" height="9" font="3">have already been shown to be associated with cardiovascular ab-</text>
<text top="487" left="303" width="157" height="9" font="3">normalities in human studies, for example,</text>
<text top="487" left="463" width="21" height="9" font="4"><i>Nodal</i></text>
<text top="487" left="484" width="2" height="9" font="3">,</text>
<text top="487" left="489" width="21" height="9" font="4"><i>GDF1</i></text>
<text top="487" left="510" width="2" height="9" font="3">,</text>
<text top="487" left="515" width="16" height="9" font="4"><i>TGF</i></text>
<text top="488" left="531" width="5" height="8" font="5"><i>β</i></text>
<text top="487" left="536" width="4" height="9" font="4"><i>3</i></text>
<text top="487" left="540" width="2" height="9" font="3">,</text>
<text top="498" left="303" width="14" height="9" font="3">and</text>
<text top="498" left="319" width="28" height="9" font="4"><i>BMPR2</i></text>
<text top="498" left="349" width="193" height="9" font="3">[Beffagna et al., 2005; Karkera et al., 2007; Mohapatra</text>
<text top="509" left="303" width="239" height="9" font="3">et al., 2009; Roberts et al., 2004; Roessler et al., 2009]. In one interest-</text>
<text top="520" left="303" width="239" height="9" font="3">ing case, a dominant-negative form of the BMP receptor ALK2 was</text>
<text top="531" left="303" width="239" height="9" font="3">found in a patient with endocardial cushion defects [Smith et al.,</text>
<text top="542" left="303" width="23" height="9" font="3">2009].</text>
<text top="553" left="312" width="230" height="9" font="3">Although a few families have been described in which CVM seg-</text>
<text top="564" left="303" width="239" height="9" font="3">regates in a Mendelian fashion, for example, due to mutations in</text>
<text top="575" left="303" width="239" height="9" font="3">cardiac transcription factors [Garg et al., 2003; Schott et al., 1998],</text>
<text top="586" left="303" width="239" height="9" font="3">these families are exceptional and usually the inheritance pattern is</text>
<text top="597" left="303" width="239" height="9" font="3">less obvious; indeed, in the majority of cases, there is a single affected</text>
<text top="608" left="303" width="239" height="9" font="3">individual in a family. On analysis of pedigrees, however, the risk is</text>
<text top="619" left="303" width="239" height="9" font="3">clearly increased in the relatives of affected individuals, indicating a</text>
<text top="630" left="303" width="239" height="9" font="3">significant genetic contribution [Burn et al., 1998; Oyen et al., 2009].</text>
<text top="641" left="303" width="239" height="9" font="3">These recurrence risks are compatible with the presence of multi-</text>
<text top="652" left="303" width="239" height="9" font="3">ple genetic risk variants of incomplete penetrance, likely interacting</text>
<text top="663" left="303" width="239" height="9" font="3">with environmental factors. We, and others, have already shown</text>
<text top="674" left="303" width="239" height="9" font="3">that incompletely penetrant alleles in key genes can predispose to</text>
<text top="685" left="303" width="239" height="9" font="3">CVM [Goldmuntz et al., 2001; Griffin et al., 2010; McElhinney et al.,</text>
<text top="696" left="303" width="239" height="9" font="3">2003; Sperling et al., 2005]. Future studies utilizing the rapidly in-</text>
<text top="707" left="303" width="239" height="9" font="3">creasing power of genome sequencing technologies to interrogate</text>
<text top="718" left="303" width="239" height="9" font="3">a much wider range of candidate genes, and eventually the whole</text>
<text top="729" left="303" width="239" height="9" font="3">exome, for rare variants that predispose to CVM will be of great</text>
<text top="740" left="303" width="239" height="9" font="3">interest. In the context of SMAD6, our results clearly demonstrate</text>
<text top="762" left="347" width="148" height="7" font="6">HUMAN MUTATION, Vol. 33, No. 4, 720–727, 2012</text>
<text top="759" left="527" width="16" height="11" font="7"><b>725</b></text>
</page>
</pdf2xml>
